It has been approved by the U.S. Food and Drug Administration (FDA) for use in early-stage and metastatic HER2-positive breast cancers as well as in metastatic, unresectable HER2-positive gastric and gastroesophageal junction cancers [7]. This evidence concerns the gene ERBB2 and breast carcinoma.